CALL/NOVO-NORDISK B/1450/0.1/16.01.26 | Market Closed - BOERSE MUENCHEN 14:26:15 2024-05-30 EDT | ||
| 0.59 EUR | -1.67% |
|
| Current month | -9.23% | ||
| 1 month | -9.23% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 24-05-30 | 0.59 | -1.67% |
| 24-05-29 | 0.6 | -3.23% |
| 24-05-28 | 0.62 | -3.13% |
| 24-05-27 | 0.64 | -1.54% |
| 24-05-24 | 0.65 | -5.80% |
Real-time BOERSE MUENCHEN
Last update May 30, 2024 at 02:26 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | Goldman Sachs |
| WKN | GG5967 |
| ISIN | DE000GG59676 |
| Date issued | 2024-03-14 |
| Strike | 1,450 kr |
| Maturity | 2026-01-16 (596 Days) |
| Parity | 10 : 1 |
| Emission price | 0.48 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.69 € |
|---|---|
| Lowest since issue | 0.465 € |
| Spread | 0.05 € |
| Spread % | 7.81% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
916.9
DKK
Average target price
917.2
DKK
Spread / Average Target
+0.04%
- Stock Market
- Warrants
- Warrant
